<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JBM</journal-id><journal-title-group><journal-title>Journal of Biosciences and Medicines</journal-title></journal-title-group><issn pub-type="epub">2327-5081</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jbm.2021.911001</article-id><article-id pub-id-type="publisher-id">JBM-112840</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  &lt;i&gt;Cedecea lapagei&lt;/i&gt; in a Patient with Multiple Injuries: Report of a Rare Case
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Xiaofan</surname><given-names>Xu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kaiyue</surname><given-names>Chang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Dongxue</surname><given-names>Song</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Guangtong</surname><given-names>Tian</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Xiaohang</surname><given-names>Hu</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Liqing</surname><given-names>Jiang</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bin</surname><given-names>Zhang</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Qingli</surname><given-names>Bie</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Shuhua</surname><given-names>Lu</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Xiaozhe</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Haixin</surname><given-names>Dong</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chengqiang</surname><given-names>Jin</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Department of Clinical Laboratory, The Affiliated Hospital of Jining Medical University, Jining, China</addr-line></aff><aff id="aff2"><addr-line>Department of Clinical Laboratory, Jining Hospital of traditional Chinese Medicine, Jining, China</addr-line></aff><aff id="aff1"><addr-line>School of Clinical Medicine, Jining Medical University, Jining, China</addr-line></aff><pub-date pub-type="epub"><day>28</day><month>10</month><year>2021</year></pub-date><volume>09</volume><issue>11</issue><fpage>1</fpage><lpage>5</lpage><history><date date-type="received"><day>28,</day>	<month>September</month>	<year>2021</year></date><date date-type="rev-recd"><day>26,</day>	<month>October</month>	<year>2021</year>	</date><date date-type="accepted"><day>29,</day>	<month>October</month>	<year>2021</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  <em>Cedecea lapagei </em>(
  <em>C. lapagei</em>) is an opportunistic pathogen in old patients with many comorbid diseases and the immunosuppressed. It is a gram-negative, facultative anaerobe bacterium of the 
  <em>Enterobacteriaceae</em> family. We present a rare case of a patient with multiple injuries, 
  <em>C. lapagei</em> was found from the exudate of the wound, what’s more, the 
  <em>Proteus vulgaris</em> was also found in blood culture medium at the same time. According to the available literature, this is the first case of simultaneous infection of two bacteria including 
  <em>C. lapagei </em>and 
  <em>Proteus vulgaris</em> from the exudate of the traumatic wound.
 
</p></abstract><kwd-group><kwd>&lt;i&gt;C. lapagei&lt;/i&gt;</kwd><kwd> &lt;i&gt;Cedecea&lt;/i&gt;</kwd><kwd> &lt;i&gt;Proteus vulgaris&lt;/i&gt;</kwd><kwd> Exudate</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>The genus Cedecea belongs to the family Enterobacteriaceae. Cedecea consists of six species and three of these species are known human pathogens: Cedecea davisae, Cedecea lapagei, and Cedecea neteri [<xref ref-type="bibr" rid="scirp.112840-ref1">1</xref>]. Although discovered in 1977, it was not until the year 2006 that the species C. lapagei became known as a pathogenic bacterium [<xref ref-type="bibr" rid="scirp.112840-ref2">2</xref>]. It has been isolated in sputum, BAL specimen, blood, etc. [<xref ref-type="bibr" rid="scirp.112840-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.112840-ref4">4</xref>], but it has not been found in exudate until now. A strain of C. lapagei was detected in the exudate from the wounded inpatient by clinic laboratory of our hospital. More important, it’s a mixed infection with Proteus vulgaris.</p></sec><sec id="s2"><title>2. Case Report</title><p>The male patient, 42 years old, a worker, was sent to our hospital due to a motorcycle fall 6 hours ago. In the emergency department, he was admitted to our hospital’s hand and foot surgical ward with “multiple injuries, multiple open fractures and dislocations of the right foot, multiple rupture of blood vessels, nerves and tendons of the right foot, skin and soft tissue defects of the right foot, pelvic fracture, hematoma of the right ilium, and fracture of the right fibula head”. The patient has clear mind, poor spirit, no obvious abnormality in heart and lung, and no water intake. He used to be in good health and had a personal history of 20 cigarettes/day for 20 years, 200 gram/day alcohol consumption for 10 years.</p><p>There was no family genetic disease or infectious history. On the day of admission, the patient was given surgical treatment. After the operation, the patient was treated with anti-bacterial, detumescence, fracture promotion, wound healing, anticoagulation, antispasmodic, and heat preservation with baking lamp. Although the wounds were well matched, there was some more liquid exudation. The patient was given iodophor disinfection, aseptic auxiliary material replacement, and the exudate was taken for bacterial culture and drug sensitivity test. Informed consent was obtained from the patient.</p></sec><sec id="s3"><title>3. Bacterial Culture and Identification</title><p>The exudate was inoculated into blood culture medium and Chinese blue culture medium, and cultured in 36˚C incubator for 24 hours. There were small round colonies with gray white, moist and smooth edges, without hemolytic ring. The microscopic examination showed Gram-negative bacteria. In addition, there were migratory membrane colonies in the blood culture medium. The round colonies and membranous colonies were identified as C. lapagei and Proteus vulgaris by Vitek™ 2 compact system (BioM&#233;rieux, France) following the manufacturer’s instructions.</p></sec><sec id="s4"><title>4. Drug Sensitivity Test</title><p>Antimicrobial susceptibility testing was determined by the automated Vitek™ 2 compact system using AST-GN13 susceptibility cards. One hundred and forty-five microliter bacterial suspension of a 0.5-McFarl and turbidity was mixed with 3 mL 0.45% NaCl solution. The AST-GN13 card filled with the mixture was used. The E. coli ATCC25922 was used as quality control. Drug sensitivity test showed that C. lapagei was resistant to Ampicillin, cefazolin, imipenem and Sulfamethoxazo. It was mediated to ampicillin/sulbactam, gentamycin, tobramycin, ciprofloxacin and levofloxacin (see <xref ref-type="table" rid="table1">Table 1</xref>). The drug sensitivity test of Proteus vulgaris showed that it was resistant to ampicillin, cefazolin, imipenem, amikacin, gentamicin, ciprofloxacin, sulfamethoxazo and sensitive to piperacillin/tazobactam, cefotaxime, ceftazidime, cefatriaxone, cefepime, aztreonam, ertap nan, levofloxacin (see <xref ref-type="table" rid="table2">Table 2</xref>).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Drug sensitivity test of C. lapagei</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >No.</th><th align="center" valign="middle" >Antibiotics</th><th align="center" valign="middle" >S/R/I (MIC, μg/ml)</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >Ampicillin</td><td align="center" valign="middle" >R (≥32)</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >Ampicillin/sulbactam</td><td align="center" valign="middle" >I (16)</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >Piperacillin/tazobactam</td><td align="center" valign="middle" >S (≤4)</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >Cefazolin</td><td align="center" valign="middle" >R (≥64)</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >Cefotaxime</td><td align="center" valign="middle" >S (≤4)</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >Ceftazidime</td><td align="center" valign="middle" >S (4)</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >Cefatriaxone</td><td align="center" valign="middle" >S (≤1)</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >Cefepime</td><td align="center" valign="middle" >S (≤1)</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >Aztreonam</td><td align="center" valign="middle" >S (≤1)</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >Ertap Nan</td><td align="center" valign="middle" >S (≤0)</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >Imipenem</td><td align="center" valign="middle" >R (4)</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >Amikacin</td><td align="center" valign="middle" >I (≤2)</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >Gentamicin</td><td align="center" valign="middle" >I (8)</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >Tobramycin</td><td align="center" valign="middle" >I (8)</td></tr><tr><td align="center" valign="middle" >15</td><td align="center" valign="middle" >Ciprofloxacin</td><td align="center" valign="middle" >I (2)</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >Levofloxacin</td><td align="center" valign="middle" >I (4)</td></tr><tr><td align="center" valign="middle" >17</td><td align="center" valign="middle" >Sulfamethoxazo</td><td align="center" valign="middle" >R (≥32)</td></tr></tbody></table></table-wrap><p>Note: MIC, minimum inhibitory concentration (μg/ml); R, resistant; S, susceptible; I, intermediate.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Drug sensitivity test of Proteus vulgaris</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >No.</th><th align="center" valign="middle" >Antibiotics</th><th align="center" valign="middle" >S/R/I (MIC, μg/ml)</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >Ampicillin</td><td align="center" valign="middle" >R (≥32)</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >Ampicillin/sulbactam</td><td align="center" valign="middle" >R (≥32)</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >Piperacillin/tazobactam</td><td align="center" valign="middle" >S (≤4)</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >Cefazolin</td><td align="center" valign="middle" >R (≥64)</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >Cefotaxime</td><td align="center" valign="middle" >S (≤4)</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >Ceftazidime</td><td align="center" valign="middle" >S (≤1)</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >Cefatriaxone</td><td align="center" valign="middle" >S (≤1)</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >Cefepime</td><td align="center" valign="middle" >S (≤1)</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >Aztreonam</td><td align="center" valign="middle" >S (≤1)</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >Ertap Nan</td><td align="center" valign="middle" >S (≤0)</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >Imipenem</td><td align="center" valign="middle" >R (4)</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >Amikacin</td><td align="center" valign="middle" >R (≥64)</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >Gentamicin</td><td align="center" valign="middle" >R (≥16)</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >Tobramycin</td><td align="center" valign="middle" >I (8)</td></tr><tr><td align="center" valign="middle" >15</td><td align="center" valign="middle" >Ciprofloxacin</td><td align="center" valign="middle" >R (≥4)</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >Levofloxacin</td><td align="center" valign="middle" >S (2)</td></tr><tr><td align="center" valign="middle" >17</td><td align="center" valign="middle" >Sulfamethoxazo</td><td align="center" valign="middle" >R (≥32)</td></tr></tbody></table></table-wrap><p>Note: MIC, minimum inhibitory concentration (μg/ml); R, resistant; S, susceptible; I, intermediate.</p></sec><sec id="s5"><title>5. Prognosis and Outcome</title><p>After changing fresh dressing for the wound once a day and constant anti-infection treatment with the addition of levofloxacin, the exudate of the wound was continuously reduced apparently. After three days, the subsequent bacterial culture and identification showed that there was no bacterial growth in the exudate. The patient was well recovered and discharged soon afterwards.</p></sec><sec id="s6"><title>6. Discussion</title><p>C. lapagei is a member of the Enterobacteriaceae family and is an uncommon opportunistic pathogen. Its susceptible population is individuals with low or suppressed immune function, such as patients with granulocytopenia, tumor chemotherapy, organ transplantation, large-scale surgery or trauma [<xref ref-type="bibr" rid="scirp.112840-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.112840-ref5">5</xref>], such as it can follow cement-related chemical burn injury [<xref ref-type="bibr" rid="scirp.112840-ref6">6</xref>]. There are very few reports of isolation of this organism from human biological samples; it is also found to be a pathogen in elderly or otherwise life-threatening conditions [<xref ref-type="bibr" rid="scirp.112840-ref7">7</xref>], for example in a patient with chronic obstructive pulmonary disease [<xref ref-type="bibr" rid="scirp.112840-ref8">8</xref>]. Biswal et al. presented a rare case of a patient with underlying malignancy of buccal mucosa, who developed an oral ulcer superinfected with C. lapagei and this is the first case of C. lapagei from India detected in a cancer patient [<xref ref-type="bibr" rid="scirp.112840-ref9">9</xref>]. C. lapagei can also cause ventilator-associated pneumonia and sepsis in Neonatal Intensive Care Unit [<xref ref-type="bibr" rid="scirp.112840-ref10">10</xref>].</p><p>We presented the first rare case of simultaneous infection of two bacteria including C. lapagei and Proteus vulgaris from the exudate of the traumatic wound in the world. But their relevance between C. lapagei and Proteus vulgaris has yet to be elucidated. It was reported that C. lapagei can produce New Delhi metallo-β-lactamase-1 (NDM-1) in some certain areas [<xref ref-type="bibr" rid="scirp.112840-ref11">11</xref>]. NDM-1 is a carbapenemase able to hydrolyze nearly all available β-lactam antibiotics, endangering efficacious antibacterial treatments [<xref ref-type="bibr" rid="scirp.112840-ref12">12</xref>]. Further studies are needed to understand its biology characteristics and the role in the mode of transmission, the spectrum of infection, and treatment options. There is a great need for physicians to cognize the emerging pathogens and know their antibiotic resistance profiles.</p></sec><sec id="s7"><title>Acknowledgements</title><p>This work was supported by the project of science and technology development research center of ministry of health (Grant number: 28-10-2), the Natural Science Foundation of Shandong Province (Grant number: ZR2010HL038), Jining Municipal Science and Technology development projects (Grant number: 2012jnjc16 &amp; 2014jnnk23), Shandong provincial medical and health science and technology development project (Grant number: 2013WS033), Shandong Province Traditional Chinese medicine science and technology development project (Grant number: 2015-244), and the Project of Shandong Province Higher Educational Science and Technology Program (Grant number: J15LL11). Nursery Program of Affiliated Hospital of Jining Medical University (Grant number: MP-2018-008).</p></sec><sec id="s8"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s9"><title>Cite this paper</title><p>Xu, X.F., Chang, K.Y., Song, D.X., Tian, G.T., Hu, X.H., Jiang, L.Q., Zhang, B., Bie, Q.L., Lu, S.H., Li, X.Z., Dong, H.X. and Jin, C.Q. (2021) Cedecea lapagei in a Patient with Multiple Injuries: Report of a Rare Case. Journal of Biosciences and Medicines, 9, 1-5. https://doi.org/10.4236/jbm.2021.911001</p></sec><sec id="s10"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.112840-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Chavez, V.R., Rosas De Silva, M.F., Alcaraz, H.O., et al. (2018) Death Related to C. lapagei in a Soft Tissue Bullae Infection: A Case Report. Journal of Medical Case Reports, 12, 328. https://doi.org/10.1186/s13256-018-1866-x</mixed-citation></ref><ref id="scirp.112840-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Davis, O. and Wall, B.M. (2006) “Broom Straw Peritonitis” Secondary to C. lapagei in a Liver Transplant Recipient. Peritoneal Dialysis International, 26, 512-513. https://doi.org/10.1177/089686080602600422</mixed-citation></ref><ref id="scirp.112840-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Yetkin, G., Ay, S., Kayabas, U., Gedik, E., Gucluer, N. and Caliskan, A. (2008) A Pneumonia Case Caused by C. lapagei. Mikrobiyoloji Bülteni, 42, 681-684.</mixed-citation></ref><ref id="scirp.112840-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ramaswamy, V.V., Gummadapu, S. and Suryanarayana, N. (2019) Nosocomial Pneumonia and Sepsis Caused by a Rare Organism C. lapagei in an Infant and a Review of Literature. BMJ Case Reports, 12, e229854. https://doi.org/10.1136/bcr-2019-229854</mixed-citation></ref><ref id="scirp.112840-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Lopez, L.A., Ibarra, B.S., de la Garza, J.A., Rada Fde, J., Nunez, A.I. and Lopez, M.G. (2013) First Reported Case of Pneumonia Caused by C. lapagei in America. Brazilian Journal of Infectious Diseases, 17, 626-628. https://doi.org/10.1016/j.bjid.2013.03.003</mixed-citation></ref><ref id="scirp.112840-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Dalamaga, M., Karmaniolas, K., Arsenis, G., Pantelaki, M., Daskalopoulou, K., Papadavid, E. and Migdalis, I. (2008) C. lapagei Bacteremia Following Cement-Related Chemical Burn Injury. Burns, 34, 1205-1207. https://doi.org/10.1016/j.burns.2007.09.001</mixed-citation></ref><ref id="scirp.112840-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kanakadandi, V.S., Sarao, M.S. and Cunningham, J.M. (2019) A Rare Case of Cedecea Davisae Bacteremia Presenting as Biliary Sepsis. Cureus, 11, e5298. https://doi.org/10.7759/cureus.5298</mixed-citation></ref><ref id="scirp.112840-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hong, S.K., Lee, J.S. and Kim, E.C. (2015) First Korean Case of C. lapagei Pneumonia in a Patient with Chronic Obstructive Pulmonary Disease. Annals of Laboratory Medicine, 35, 266-268. https://doi.org/10.3343/alm.2015.35.2.266</mixed-citation></ref><ref id="scirp.112840-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Biswal, I., Hussain, N.A. and Grover, R.K. (2015) C. lapagei in a Patient with Malignancy: Report of a Rare Case. Journal of Cancer Research and Therapeutics, 11, 646. https://doi.org/10.4103/0973-1482.147736</mixed-citation></ref><ref id="scirp.112840-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Kury, C.M.H., Yabrudi, A.A., de Souza, T.B., et al. (2017) First Reported Case of Ventilator-Associated Pneumonia and Sepsis Caused by C. lapagei in a Brazilian Neonatal Intensive Care Unit. Journal of the Pediatric Infectious Diseases Society, 6, 209-210. https://doi.org/10.1093/jpids/piw077</mixed-citation></ref><ref id="scirp.112840-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ahmad, N., Ali, S.M. and Khan, A.U. (2017) First Reported New Delhi Metallo-Beta-Lactamase-1-Producing C. lapagei. International Journal of Antimicrobial Agents, 49, 118-119. https://doi.org/10.1016/j.ijantimicag.2016.10.001</mixed-citation></ref><ref id="scirp.112840-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Linciano, P., Cendron, L., Gianquinto, E., Spyrakis, F. and Tondi, D. (2019) Ten Years with New Delhi Metallo-Beta-Lactamase-1 (NDM-1): From Structural Insights to Inhibitor Design. ACS Infectious Diseases, 5, 9-34. https://doi.org/10.1021/acsinfecdis.8b00247</mixed-citation></ref></ref-list></back></article>